At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Aug 21, 2026 at 16:08 ET
Two insiders at Arcutis Biotherapeutics sold a combined $170K in open-market sales over a week. Director Welgus Howard G. also exercised multiple derivative tranches for a net cash outlay of ~$32K, then sold the resulting shares at market prices. The total dollar value is only ~0.005% of ARQT's $3.2B market cap, making this a trivial cluster by proportionality standards. The sales are likely liquidity-driven following option exercises, not a bearish signal on the company's fundamentals.
- Two insiders sold a total of $170K in open-market sales over 7 days.
- Director Welgus Howard G. exercised 8,192 derivative shares (cash outlay ~$32K) and sold 4,730 shares at $26.18 for $124K.
- Total sales represent ~0.005% of ARQT's $3.2B market cap, immaterial by academic proportionality thresholds.
- No C-suite executives participated in the selling; the cluster is limited to a director and a 'See Remarks' officer.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access